The Laboratory of Pharmacology of Angiogenesis conducts research on the pharmacology of angiogenesis and microcirculation, on the cellular and molecular mechanisms of physiological and pathological angiogenesis, in particular in inflammatory, degenerative and neoplastic diseases, on the characterization of pro- and antiangiogenic factors in the progression of diseases and for therapeutic exploitation, on molecular/methobic biomarkers for stability and resistance to anticancer drugs, on pharmacogenetics and personalized medicine in oncology. Research is carried out through an integrated in vitro test platform, using a wide range of cell lines (endothelial, vascular and stromal cells, human and murine cancer cells, naive and genetically modified cells), on which molecular biology studies (expression/protein activity using western blot and immunofluorescence techniques) are performed, EIA/ELISA tests for mediators and metabolic pathways, RT-PCR for gene expression, silencing and transfection of target genes) and in vitro functional tests (cell proliferation and survival, toxicity and cyto-compatibilitys, cell migration, clonogenic assay, tumour formation and many others).